<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557501</url>
  </required_header>
  <id_info>
    <org_study_id>20.208</org_study_id>
    <nct_id>NCT04557501</nct_id>
  </id_info>
  <brief_title>PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer</brief_title>
  <acronym>PATRON</acronym>
  <official_title>PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Society (CCS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tom Baker Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Health Economics, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kingston Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the conduct of a Phase III randomized controlled trial, investigators plan to: 1)&#xD;
      determine if PSMA PET/CT guided intensification of radiotherapy or surgery improves cancer&#xD;
      outcomes compared to conventional imaging-guided therapy in patients at risk of advanced&#xD;
      disease, 2) evaluate its impact on toxicity and quality of life, and 3) measure the&#xD;
      cost-effectiveness of the PSMA PET/CT guided approach.&#xD;
&#xD;
      Participants with high-risk prostate cancer planned for curative-intent standard-of-care&#xD;
      radiotherapy or surgery, or with biochemical failure after radical prostatectomy planned for&#xD;
      salvage radiotherapy will be enrolled over 3 years (n=776). Those randomized to the&#xD;
      investigational arm will have PSMA PET/CT prior to therapy. Based on the imaging results,&#xD;
      treating physicians will intensify radiotherapy or surgery unless widely metastatic disease&#xD;
      is found, in which case systemic therapy will be intensified.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PSMA PET/CT, particularly with the new generation [18F]DCFPyL radiotracer, has substantially&#xD;
      improved our ability to detect sites of prostate cancer compared with conventional imaging&#xD;
      alone. When combined with innovative radiotherapeutic and surgical techniques that can now&#xD;
      safely target and ablate such disease sites, next generation imaging is now poised to&#xD;
      transform the therapeutic paradigm for patients at risk of advanced cancer.&#xD;
&#xD;
      Investigators postulate that intensification of radiotherapy or surgery based on the results&#xD;
      of PSMA PET/CT will improve cancer control outcomes in a cost-effective manner, with minimal&#xD;
      toxicity, and an overall improvement in quality of life in the longer term.&#xD;
&#xD;
      Investigators expect to show that PSMA PET/CT will have a direct and profound impact on&#xD;
      radiotherapy and surgery practice, translating to improved failure-free survival outcomes in&#xD;
      patients at risk of advanced prostate cancer. The subset of patients potentially impacted is&#xD;
      broad, including patients recurring after prostatectomy and newly presenting patients with&#xD;
      high-risk features. Although PSMA PET/CT is increasingly making its way into clinical&#xD;
      practice around the world, Canadian provinces will need to make an informed decision of&#xD;
      whether to fund this imaging for our patients. The high-level evidence gathered in this trial&#xD;
      is desperately needed to assess the impact on patient outcomes and, in doing so, justify&#xD;
      broad access and reimbursement for patients with prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if PSMA PET/CT guided intensification of therapy is superior to standard of care (SOC) therapy as measured by improved failure-free survival (FFS).</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of toxicity (CTCAE)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent next-line therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EPIC 26)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New lesion detection yield (on PSMA PET/CT)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of PMSA PET/CT on RT or surgical management (rate of treatment intensification)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness (EQ5D5L)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">776</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Control - SOC Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental - PSMAiTx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA PET/CT guided intensification of therapy</intervention_name>
    <description>PSMA PET/CT prior to treatment.</description>
    <arm_group_label>Experimental - PSMAiTx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Arm</intervention_name>
    <description>Control - Treatment without PSMA PET/CT</description>
    <arm_group_label>Control - SOC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of adenocarcinoma of the prostate planned for curative-intent&#xD;
             standard-of-care radiotherapy (primary or salvage post prostatectomy) or radical&#xD;
             prostatectomy with lymph node dissection.&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  High risk of regional or distant metastases as defined by any of:&#xD;
&#xD;
          -  Newly diagnosed and untreated prostate cancer with CAPRA score 6-10, or stage cN1.&#xD;
&#xD;
          -  Prior history of radical prostatectomy and biochemical failure (PSA&gt;0.1ng/mL).&#xD;
&#xD;
          -  Patients must provide study-specific informed consent prior to study entry.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or prior androgen deprivation therapy (except 5-alpha reductase inhibitor)&#xD;
             terminated &lt; 12 months prior to enrollment.&#xD;
&#xD;
          -  Prior or planned PSMA PET/CT scan outside of this clinical trial.&#xD;
&#xD;
          -  Charlson Comorbidity Index &gt; 5 (see Appendix 2).&#xD;
&#xD;
          -  Prior curative intent treatment for prostate cancer with local therapy other than&#xD;
             surgery (primary radiotherapy or ablative therapies)&#xD;
&#xD;
          -  Evidence of extra-pelvic nodal disease (M1a) on conventional imaging (if performed)&#xD;
&#xD;
          -  Evidence of metastatic disease (M1b bone, M1c viscera/soft tissue) on conventional&#xD;
             imaging (if performed)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cindy Prie</last_name>
    <phone>514-890-8254</phone>
    <email>cindy.prie.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Ménard</last_name>
    <email>cynthia.menard@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Allard</last_name>
      <email>josee.allard@chudequebec.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Pouliot</last_name>
      <email>sophie.pouliot@chudequebec.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Vigneault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Morneau</last_name>
      <phone>819-346-1110 x12827</phone>
      <email>elsie.morneau.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Couture</last_name>
      <phone>819-346-1110 x14311</phone>
      <email>sophie.couture.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Richard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Prie</last_name>
      <phone>514-655-0390</phone>
      <email>cindy.prie.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Cynthia Menard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

